Drug intelligence / Profile preview

Shugan Jianpi

Development stage: Preclinical
Lead developer: KPC Pharmaceuticals
Administration: Topical

Overview

Shugan Jianpi is a Traditional Chinese Medicine (TCM) formulation administered as an acupoint application (plaster). It is being investigated for its therapeutic effects in combination with antiviral drugs for the treatment of chronic hepatitis B, specifically addressing the TCM pattern of stagnation of liver qi and spleen deficiency.

Other names: Shugan Jianpi plaster

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on Shugan Jianpi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shugan Jianpi.

Explore the full profile